Skip to main content
    I

    ImmuCell Corporation (ICCC)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $11.33
    -0.09 (-0.79%)

    Market Cap: $103.82M

    Last updated: Nov 17, 2026 at 4:10 PM ET

    ImmuCell Corporation (ICCC) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    ImmuCell (ICCC) has a market cap of $103.82M and an enterprise value of $103.81M. Its trailing P/E is 56.7x.

    Total Valuation

    Enterprise value is 0.01% below the market cap, as cash exceeds debt.

    Market Cap$103.82M
    Enterprise Value$103.81M
    Latest price (Nov 17, 2026)$11.33

    Key Dates

    The next earnings report is expected on Mar 2, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 2, 2027 (expected)
    Last Earnings DateNov 12, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.22% in the quarter ended Sep 30, 2026 and grew 5.48% a year over 2 years.

    Shares Outstanding9.08M
    Shares Change (YoY)+0.43%
    Shares Change (QoQ)+0.22%
    Share Count Growth (2Y CAGR)+5.48%

    Valuation Ratios

    Sales and book value multiples are 3.1x and 3.1x.

    P/E Ratio56.7x
    P/S Ratio3.1x
    P/B Ratio3.1x
    P/TBV Ratio3.1x
    P/FCF Ratio19.1x
    P/OCF Ratio13.3x

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 25.1x EBITDA and 19.1x free cash flow.

    EV / Earnings55.2x
    EV / Sales3.1x
    EV / EBITDA25.1x
    EV / EBIT53.9x
    EV / FCF19.1x

    Price Statistics

    The stock is up 109.81% over 52 weeks and trades 11.52% above its 50-day average.

    Beta (1Y)0.31
    52-Week Change+109.81%
    1-Month Change+7.80%
    3-Month Change+11.85%
    6-Month Change+11.08%
    5-Year Change+16.59%
    10-Year Change+83.54%
    Total Return (1Y)+109.81%
    Total Return (3Y CAGR)+33.50%
    Total Return (5Y CAGR)+4.88%
    Return vs SPY (1Y)+136.91%
    Max Drawdown (1Y)-18.26%
    Max Drawdown (3Y)-40.00%
    Sharpe Ratio (1Y)1.91
    Correlation with SPY (1Y)0.09
    50-Day Average$10.16
    200-Day Average$9.11
    52-Week Range$4.52 to $12.10
    RSI (14 Days)65.7
    Average Volume (20 Days)13.42K

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 4.61x current liabilities, and total debt is 0.24x shareholder equity.

    Current Ratio4.61x
    Quick Ratio2.50x
    Debt / Equity0.24x
    Debt / EBITDA1.93x
    Debt / FCF1.46x

    Returns and Efficiency

    Return on invested capital is 4.62% over the last 12 months, against a 5-year average of -6.08%.

    Return on Equity (ROE)5.74%
    Return on Assets (ROA)3.92%
    Return on Invested Capital (ROIC)4.62%
    Return on Capital Employed (ROCE)4.45%
    ROE (5Y Average)-8.65%
    ROA (5Y Average)-5.23%
    ROIC (5Y Average)-6.08%
    Asset Turnover0.71x
    Inventory Turnover2.08x
    Receivables Turnover10.59x
    Cash Conversion Cycle155 days

    Taxes

    Income tax took 2.31% of pretax income over the last 12 months.

    Income Tax (TTM)$44.54K
    Effective Tax Rate2.31%

    Scores

    ICCC has an Altman Z-Score of 5.01, in the safe zone above 2.99, and a Piotroski F-Score of 7 of 9, in the average band of 3 to 7.

    Altman Z-Score5.01
    Altman Z ZoneSafe
    Piotroski F-Score7 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $33.21M over the last 12 months is up 19.59% from the 12 months before.

    Revenue$33.21M
    Revenue Growth (YoY)+19.59%
    Gross Profit$13.56M
    Operating Income$4.80M
    Pretax Income$1.92M
    Net Income$1.88M
    EBIT$1.92M
    Reported EPS (TTM)$0.20

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 68.33% of the $47.96M in total assets.

    Cash and Equivalents$7.91M
    Total Debt$7.90M
    Net Cash$15.56K
    Net Cash Per Share$0.00
    Working Capital$16.90M
    Shareholder Equity$32.77M
    Book Value Per Share$3.61
    Tangible Book Value$32.68M
    Tangible Book Per Share$3.60
    Total Assets$47.96M
    Total Liabilities$15.18M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $2.43M of capital spending, operating cash flow left $5.40M of free cash flow.

    Operating Cash Flow$7.83M
    Capital Expenditures$2.43M
    Free Cash Flow$5.40M
    FCF Per Share$0.59
    Depreciation and Amortization$2.18M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is 14.47%, against a 5-year average of -8.83%.

    Gross Margin40.83%
    Operating Margin14.47%
    Pretax Margin5.79%
    Net Margin5.66%
    EBIT Margin5.79%
    FCF Margin16.27%
    Gross Margin (5Y Average)35.94%
    Operating Margin (5Y Average)-8.83%
    Net Margin (5Y Average)-11.76%

    Growth

    Revenue grew 14.19% a year over 3 years.

    Revenue Growth (3Y CAGR)+14.19%
    Revenue Growth (5Y CAGR)+12.50%
    Book Value Per Share Growth (2Y CAGR)-3.70%
    Tangible Book Per Share Growth (2Y CAGR)-3.61%

    Revenue and profit by year

    Dividends and Yields

    ICCC does not pay a dividend. Its free cash flow yield is 5.25%.

    Earnings Yield1.76%
    FCF Yield5.25%
    Buyback Yield0.00%
    Shareholder Yield0.00%

    Peer Position

    Against 6 similar companies, ICCC has the 5th highest P/S.

    P/S Ratio3.1x vs 17.4x median
    ROIC4.62% vs -147.29% median
    Revenue Growth (Trailing 4 Quarters, YoY)+19.59% vs -64.32% median

    Competitors compared

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewFairly valued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About ICCC

    What is ICCC's market cap?

    ImmuCell has a market cap of $103.82M. Its enterprise value, which adds debt and subtracts cash, is $103.81M.

    What is ICCC's P/E ratio?

    ImmuCell has a trailing P/E ratio of 56.7x.

    How many shares of ICCC are outstanding?

    ImmuCell has 9.08M shares outstanding. The count is up 0.43% from a year earlier.

    Does ICCC pay a dividend?

    No. ImmuCell does not pay a dividend.

    How much debt does ICCC have?

    ImmuCell has $7.90M of total debt and $7.91M of cash and equivalents, a net cash position of $15.56K.